The Asthma Disease Activity Score: A discriminating, responsive measure predicts future asthma attacks

Journal of Allergy and Clinical Immunology

Volumn 130, Issue 5, 2012, Pages

  Greenberg, Steven ^a,b   Liu, Nancy ^a   Kaur, Amarjot ^a   Lakshminarayanan, Mani ^a   Zhou, Yijie ^a   Nelsen, Linda ^a   Gates Jr , Davis F ^a   Kuo, Wen Ling ^a   Smugar, Steven S ^a   Reiss, Theodore F ^a   Barnes, Neil ^c   Fuhlbrigge, Anne ^d   Milgrom, Henry ^e   Schatz, Michael ^f   Knorr, Barbara ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b College of Physicians and Surgeons ^*  (United States)

^c BARTS HEALTH NHS TRUST   (United Kingdom)

^d HARVARD VANGUARD MEDICAL ASSOCIATES   (United States)

^e Children's Hospital Colorado   (United States)

^f KAISER PERMANENTE   (United States)

Author keywords

activity; Asthma; asthma specific quality of life; exacerbations; regression; validity

Indexed keywords

BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; MONTELUKAST;

ARTICLE; ASTHMA; ASTHMA DISEASE ACTIVITY SCORE 4 - VARIABLE VERSION; ASTHMA DISEASE ACTIVITY SCORE 6; ASTHMA QUALITY OF LIFE QUESTIONNAIRE-SYMPTOM DOMAIN; CONTENT VALIDITY; DISCRIMINANT ANALYSIS; DISEASE ACTIVITY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG UTILIZATION; FORCED EXPIRATORY VOLUME; HUMAN; MULTIPLE REGRESSION; NOCTURNAL AWAKENING; OUTCOME ASSESSMENT; PEAK EXPIRATORY FLOW DIURNAL VARIABILITY; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTIVE VALIDITY; PRIORITY JOURNAL; RESPIRATORY TRACT PARAMETERS; RISK ASSESSMENT; SAMPLE SIZE; SCORING SYSTEM; SYMPTOMATOLOGY; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84869118334     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2012.07.057     Document Type: Article

References (20)

1. E.F. Juniper, P.M. O'Byrne, G.H. Guyatt, P.J. Ferrie, and D.R. King Development and validation of a questionnaire to measure asthma control Eur Respir J 14 1999 902 907 (Pubitemid 29519356)
2. R.A. Nathan, C.A. Sorkness, M. Kosinski, M. Schatz, J.T. Li, and P. Marcus Development of the asthma control test: a survey for assessing asthma control J Allergy Clin Immunol 113 2004 59 65 (Pubitemid 38096162)
3. M.M. Cloutier, M. Schatz, M. Castro, N. Clark, H.W. Kelly, and R. Mangione-Smith Asthma outcomes: composite scores of asthma control J Allergy Clin Immunol 129 suppl 2012 S24 S33
4. A.M. van Gestel, M.L. Prevoo, M.A. van 't Hof, M.H. van Rijswijk, L.B. van de Putte, and P.L. van Riel Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria Arthritis Rheum 39 1996 34 40 (Pubitemid 26036375)
5. J. Zhang, C. Yu, S.T. Holgate, and T.F. Reiss Variability and lack of predictive ability of asthma end-points in clinical trials Eur Respir J 20 2002 1102 1109 (Pubitemid 35331865)
6. G.P. Anderson Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease Lancet 372 2008 1107 1119
7. J. Lotvall, C.A. Akdis, L.B. Bacharier, L. Bjermer, T.B. Casale, and A. Custovic Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome J Allergy Clin Immunol 127 2011 355 360
8. K. Malmstrom, G. Rodriguez-Gomez, J. Guerra, C. Villaran, A. Pineiro, and L.X. Wei Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group Ann Intern Med 130 1999 487 495 (Pubitemid 29135801)
9. T.F. Reiss, P. Chervinsky, R.J. Dockhorn, S. Shingo, B. Seidenberg, and T.B. Edwards Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group Arch Intern Med 158 1998 1213 1220
10. S. Greenberg, N. Liu, A. Kaur, M. Lakshminarayanan, Y. Zhou, and L.M. Nelsen Airway obstruction lability helps distinguish levels of disease activity in asthma Respir Med 106 2012 500 507
11. D.M. van der Heijde, M.A. 't Hof, P.L. van Riel, L.A. Theunisse, E.W. Lubberts, and M.A. van Leeuwen Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score Ann Rheum Dis 49 1990 916 920 (Pubitemid 20360757)
12. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. 2008.
13. EPR Expert panel report: guidelines for the diagnosis and management of asthma (EPR 3-2007) 2007 US Department of Health and Human Services; National Institutes of Health; National Heart, Lung, and Blood Institute; National Asthma Education and Prevention Program Bethesda NIH publication no. 08-5846
14. H.K. Reddel, D.R. Taylor, E.D. Bateman, L.P. Boulet, H.A. Boushey, and W.W. Busse An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice Am J Respir Crit Care Med 180 2009 59 99
15. J.Y. King, R. Ferrara, R. Tabibiazar, J.M. Spin, M.M. Chen, and A. Kuchinsky Pathway analysis of coronary atherosclerosis Physiol Genomics 23 2005 103 118
16. R.A. Nathan, H. Nolte, and D.S. Pearlman Twenty-six-week efficacy and safety study of mometasone furoate/formoterol 200/10 microg combination treatment in patients with persistent asthma previously receiving medium-dose inhaled corticosteroids Allergy Asthma Proc 31 2010 269 279
17. J. Fransen, M.C. Creemers, and P.L. van Riel Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria Rheumatology (Oxford) 43 2004 1252 1255 (Pubitemid 39359299)
18. W. Busse, J. Corren, B.Q. Lanier, M. McAlary, A. Fowler-Taylor, and G.D. Cioppa Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma J Allergy Clin Immunol 108 2001 184 190 (Pubitemid 32735398)
19. H. Milgrom, W. Berger, A. Nayak, N. Gupta, S. Pollard, and M. McAlary Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab) Pediatrics 108 2001 E36
20. M. Soler, J. Matz, R. Townley, R. Buhl, J. O'Brien, and H. Fox The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics Eur Respir J 18 2001 254 261 (Pubitemid 32776398)